NO323861B1 - Fremgangsmate ved utvinning av hoyren vWF eller faktor VIII/vWF-kompleks - Google Patents

Fremgangsmate ved utvinning av hoyren vWF eller faktor VIII/vWF-kompleks Download PDF

Info

Publication number: NO323861B1
Authority: NO; Norway
Prior art keywords: vwf; factor viii; complex; stated; purified
Prior art date: 1997-02-27

Application number

NO19994084A

Other languages

English (en)

Norwegian (no)

Other versions

NO994084L (no

NO994084D0 (no

Inventor

Friedrich Dorner

Johann Eibl

Bernhard Fischer

Artur Mitterer

Christian Fiedler

Original Assignee

Baxter Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-02-27

Filing date

1999-08-24

Publication date

2007-07-16

1999-08-24 Application filed by Baxter Ag filed Critical Baxter Ag

1999-08-24 Publication of NO994084D0 publication Critical patent/NO994084D0/no

1999-10-19 Publication of NO994084L publication Critical patent/NO994084L/no

2007-07-16 Publication of NO323861B1 publication Critical patent/NO323861B1/no

Links

108010054218 Factor VIII Proteins 0.000 title claims description 130
102000001690 Factor VIII Human genes 0.000 title claims description 130
229960000301 factor viii Drugs 0.000 title claims description 130
238000000034 method Methods 0.000 title claims description 65
238000011084 recovery Methods 0.000 title description 7
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 43
235000001014 amino acid Nutrition 0.000 claims description 28
150000001413 amino acids Chemical class 0.000 claims description 28
239000000427 antigen Substances 0.000 claims description 24
239000004471 Glycine Substances 0.000 claims description 22
102000036639 antigens Human genes 0.000 claims description 22
108091007433 antigens Proteins 0.000 claims description 22
238000004587 chromatography analysis Methods 0.000 claims description 21
239000003480 eluent Substances 0.000 claims description 21
239000012634 fragment Substances 0.000 claims description 17
239000003795 chemical substances by application Substances 0.000 claims description 15
239000000243 solution Substances 0.000 claims description 15
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 13
229960002897 heparin Drugs 0.000 claims description 13
229920000669 heparin Polymers 0.000 claims description 13
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 11
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 11
230000003196 chaotropic effect Effects 0.000 claims description 10
230000007935 neutral effect Effects 0.000 claims description 10
239000003381 stabilizer Substances 0.000 claims description 10
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 9
235000004279 alanine Nutrition 0.000 claims description 9
-1 p-alanine Chemical compound 0.000 claims description 8
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 7
241000700605 Viruses Species 0.000 claims description 7
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 7
KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 6
230000002779 inactivation Effects 0.000 claims description 6
238000011210 chromatographic step Methods 0.000 claims description 5
239000007864 aqueous solution Substances 0.000 claims description 4
229960003237 betaine Drugs 0.000 claims description 4
239000004480 active ingredient Substances 0.000 claims description 2
KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims 2
108010047303 von Willebrand Factor Proteins 0.000 description 234
102100036537 von Willebrand factor Human genes 0.000 description 229
229960001134 von willebrand factor Drugs 0.000 description 229
230000000694 effects Effects 0.000 description 38
235000018102 proteins Nutrition 0.000 description 31
108090000623 proteins and genes Proteins 0.000 description 31
102000004169 proteins and genes Human genes 0.000 description 31
238000000746 purification Methods 0.000 description 31
239000000872 buffer Substances 0.000 description 25
229940024606 amino acid Drugs 0.000 description 24
238000010828 elution Methods 0.000 description 22
238000002360 preparation method Methods 0.000 description 22
229960002449 glycine Drugs 0.000 description 20
102100026735 Coagulation factor VIII Human genes 0.000 description 16
101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 16
229960003767 alanine Drugs 0.000 description 12
230000027455 binding Effects 0.000 description 12
238000007792 addition Methods 0.000 description 9
230000008859 change Effects 0.000 description 9
238000003795 desorption Methods 0.000 description 9
229960002885 histidine Drugs 0.000 description 9
230000003993 interaction Effects 0.000 description 9
238000001042 affinity chromatography Methods 0.000 description 8
201000003542 Factor VIII deficiency Diseases 0.000 description 7
239000004365 Protease Substances 0.000 description 7
230000023555 blood coagulation Effects 0.000 description 7
210000004027 cell Anatomy 0.000 description 7
239000007858 starting material Substances 0.000 description 7
239000000126 substance Substances 0.000 description 7
241000699666 Mus <mouse, genus> Species 0.000 description 6
230000008901 benefit Effects 0.000 description 6
238000004113 cell culture Methods 0.000 description 6
238000010494 dissociation reaction Methods 0.000 description 6
230000005593 dissociations Effects 0.000 description 6
239000000203 mixture Substances 0.000 description 6
238000011109 contamination Methods 0.000 description 5
239000003446 ligand Substances 0.000 description 5
229960005190 phenylalanine Drugs 0.000 description 5
230000008569 process Effects 0.000 description 5
239000012460 protein solution Substances 0.000 description 5
238000000926 separation method Methods 0.000 description 5
238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 5
108010049003 Fibrinogen Proteins 0.000 description 4
102000008946 Fibrinogen Human genes 0.000 description 4
208000009292 Hemophilia A Diseases 0.000 description 4
108091005804 Peptidases Proteins 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
238000005571 anion exchange chromatography Methods 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
229940012952 fibrinogen Drugs 0.000 description 4
239000012467 final product Substances 0.000 description 4
239000000825 pharmaceutical preparation Substances 0.000 description 4
208000011580 syndromic disease Diseases 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
239000004475 Arginine Substances 0.000 description 3
102000015081 Blood Coagulation Factors Human genes 0.000 description 3
108010039209 Blood Coagulation Factors Proteins 0.000 description 3
102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
239000004472 Lysine Substances 0.000 description 3
108090000526 Papain Proteins 0.000 description 3
102000035195 Peptidases Human genes 0.000 description 3
229920002684 Sepharose Polymers 0.000 description 3
150000001450 anions Chemical class 0.000 description 3
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
229960003121 arginine Drugs 0.000 description 3
239000001110 calcium chloride Substances 0.000 description 3
229910001628 calcium chloride Inorganic materials 0.000 description 3
235000011148 calcium chloride Nutrition 0.000 description 3
239000012141 concentrate Substances 0.000 description 3
238000000605 extraction Methods 0.000 description 3
238000000855 fermentation Methods 0.000 description 3
230000004151 fermentation Effects 0.000 description 3
238000002523 gelfiltration Methods 0.000 description 3
238000004255 ion exchange chromatography Methods 0.000 description 3
229920002521 macromolecule Polymers 0.000 description 3
239000000463 material Substances 0.000 description 3
239000011159 matrix material Substances 0.000 description 3
235000019834 papain Nutrition 0.000 description 3
229940055729 papain Drugs 0.000 description 3
NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
239000000047 product Substances 0.000 description 3
239000011347 resin Substances 0.000 description 3
229920005989 resin Polymers 0.000 description 3
VGTPCRGMBIAPIM-UHFFFAOYSA-M sodium thiocyanate Chemical compound [Na+].[S-]C#N VGTPCRGMBIAPIM-UHFFFAOYSA-M 0.000 description 3
208000010110 spontaneous platelet aggregation Diseases 0.000 description 3
230000006641 stabilisation Effects 0.000 description 3
238000011105 stabilization Methods 0.000 description 3
230000000087 stabilizing effect Effects 0.000 description 3
238000012360 testing method Methods 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
102100037362 Fibronectin Human genes 0.000 description 2
108010067306 Fibronectins Proteins 0.000 description 2
208000032843 Hemorrhage Diseases 0.000 description 2
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
108010094028 Prothrombin Proteins 0.000 description 2
108010081391 Ristocetin Proteins 0.000 description 2
QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 2
230000000740 bleeding effect Effects 0.000 description 2
239000003114 blood coagulation factor Substances 0.000 description 2
229940019700 blood coagulation factors Drugs 0.000 description 2
239000006227 byproduct Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
BGTFCAQCKWKTRL-YDEUACAXSA-N chembl1095986 Chemical compound C1[C@@H](N)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]([C@H]1C(N[C@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(C(=C(O)C=4)C)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@@H](C(=O)N3)[C@H](O)C=3C=CC(O4)=CC=3)C(=O)N1)C(O)=O)=O)C(C=C1)=CC=C1OC1=C(O[C@@H]3[C@H]([C@H](O)[C@@H](O)[C@H](CO[C@@H]5[C@H]([C@@H](O)[C@H](O)[C@@H](C)O5)O)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@H](O)[C@@H](CO)O3)O)C4=CC2=C1 BGTFCAQCKWKTRL-YDEUACAXSA-N 0.000 description 2
238000011097 chromatography purification Methods 0.000 description 2
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical group BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 2
239000000539 dimer Substances 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000012528 membrane Substances 0.000 description 2
238000012261 overproduction Methods 0.000 description 2
239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
230000004962 physiological condition Effects 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
230000017854 proteolysis Effects 0.000 description 2
239000012264 purified product Substances 0.000 description 2
229950004257 ristocetin Drugs 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
238000001179 sorption measurement Methods 0.000 description 2
XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
238000005406 washing Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 1
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
101710186708 Agglutinin Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
102100022641 Coagulation factor IX Human genes 0.000 description 1
102100023804 Coagulation factor VII Human genes 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
108010076282 Factor IX Proteins 0.000 description 1
108010014172 Factor V Proteins 0.000 description 1
108010023321 Factor VII Proteins 0.000 description 1
108010061932 Factor VIIIa Proteins 0.000 description 1
108010014173 Factor X Proteins 0.000 description 1
108010074864 Factor XI Proteins 0.000 description 1
108010080865 Factor XII Proteins 0.000 description 1
102000000429 Factor XII Human genes 0.000 description 1
108010040721 Flagellin Proteins 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
208000031220 Hemophilia Diseases 0.000 description 1
101710146024 Horcolin Proteins 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
101001082397 Human adenovirus B serotype 3 Hexon-associated protein Proteins 0.000 description 1
102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
101710189395 Lectin Proteins 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
101710179758 Mannose-specific lectin Proteins 0.000 description 1
101710150763 Mannose-specific lectin 1 Proteins 0.000 description 1
101710150745 Mannose-specific lectin 2 Proteins 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
102100027378 Prothrombin Human genes 0.000 description 1
101001120093 Pseudoalteromonas phage PM2 Protein P8 Proteins 0.000 description 1
241000589516 Pseudomonas Species 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
108010077895 Sarcosine Proteins 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
108010046334 Urease Proteins 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000000910 agglutinin Substances 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
239000012491 analyte Substances 0.000 description 1
238000005349 anion exchange Methods 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
108010083526 asialo-von Willebrand Factor Proteins 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
238000003556 assay Methods 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
229960000182 blood factors Drugs 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
238000005277 cation exchange chromatography Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
229960002173 citrulline Drugs 0.000 description 1
235000013477 citrulline Nutrition 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
239000000470 constituent Substances 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
108010065137 cryobulin Proteins 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000011033 desalting Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
229960004222 factor ix Drugs 0.000 description 1
229940012413 factor vii Drugs 0.000 description 1
229940012426 factor x Drugs 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
238000006062 fragmentation reaction Methods 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
229960003692 gamma aminobutyric acid Drugs 0.000 description 1
238000001641 gel filtration chromatography Methods 0.000 description 1
238000007429 general method Methods 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
229960002743 glutamine Drugs 0.000 description 1
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
231100000086 high toxicity Toxicity 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
238000002955 isolation Methods 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
229960003136 leucine Drugs 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
238000012792 lyophilization process Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
229960004452 methionine Drugs 0.000 description 1
238000002156 mixing Methods 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
239000013642 negative control Substances 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
230000001376 precipitating effect Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
238000012545 processing Methods 0.000 description 1
229960002429 proline Drugs 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
235000019419 proteases Nutrition 0.000 description 1
230000004952 protein activity Effects 0.000 description 1
238000000751 protein extraction Methods 0.000 description 1
229940039716 prothrombin Drugs 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
229940043230 sarcosine Drugs 0.000 description 1
230000007017 scission Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
229960001153 serine Drugs 0.000 description 1
239000007787 solid Substances 0.000 description 1
241000894007 species Species 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
210000004988 splenocyte Anatomy 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000011146 sterile filtration Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000000725 suspension Substances 0.000 description 1
229960003080 taurine Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
229960002898 threonine Drugs 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
229960004799 tryptophan Drugs 0.000 description 1
229960004441 tyrosine Drugs 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/824—Immunological separation techniques
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T436/108331—Preservative, buffer, anticoagulant or diluent
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/25125—Digestion or removing interfering materials
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/2525—Stabilizing or preserving
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/25375—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/25375—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]
- Y10T436/255—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.] including use of a solid sorbent, semipermeable membrane, or liquid extraction

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Hematology (AREA)
Veterinary Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Toxicology (AREA)
Zoology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Diabetes (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Treatment Of Liquids With Adsorbents In General (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

NO19994084A 1997-02-27 1999-08-24 Fremgangsmate ved utvinning av hoyren vWF eller faktor VIII/vWF-kompleks NO323861B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
AT0033997A AT406867B (de)	1997-02-27	1997-02-27	Verfahren zur gewinnung von hochreinem vwf oder faktor viii/vwf-komplex
PCT/AT1998/000033 WO1998038218A1 (fr)	1997-02-27	1998-02-18	PROCEDE PERMETTANT D'OBTENIR UN FACTEUR DE VON WILLEBRAND (vWF) OU UN COMPLEXE FACTEUR VIII

Publications (3)

Publication Number	Publication Date
NO994084D0 NO994084D0 (no)	1999-08-24
NO994084L NO994084L (no)	1999-10-19
NO323861B1 true NO323861B1 (no)	2007-07-16

Family

ID=3487975

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19994084A NO323861B1 (no)	1997-02-27	1999-08-24	Fremgangsmate ved utvinning av hoyren vWF eller faktor VIII/vWF-kompleks

Country Status (13)

Country	Link
US (1)	US6579723B1 (fr)
EP (1)	EP1012191B1 (fr)
JP (1)	JP4250769B2 (fr)
AR (2)	AR010120A1 (fr)
AT (2)	AT406867B (fr)
AU (1)	AU734277B2 (fr)
CA (1)	CA2282842C (fr)
DE (1)	DE59813968D1 (fr)
DK (1)	DK1012191T3 (fr)
ES (1)	ES2285758T3 (fr)
NO (1)	NO323861B1 (fr)
SI (1)	SI1012191T1 (fr)
WO (1)	WO1998038218A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6926894B2 (en)	2000-11-22	2005-08-09	Baxter Aktiengesellschaft	Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
JP3862613B2 (ja)	2002-06-05	2006-12-27	キヤノン株式会社	画像処理装置及び画像処理方法並びにコンピュータプログラム
DE10246125A1 (de)	2002-10-01	2004-04-15	Aventis Behring Gmbh	Konzentrat eines Faktor VIII:C-haltigen von-Willebrand-Faktors und das dazu gehörige Verfahren
FR2874216B1 (fr) *	2004-08-16	2006-11-03	Lab Francais Du Fractionnement	Procede de preparation d'un concentre de facteur von willebrand (fvw) par voie chromatographique et concentre de fvw susceptible d'etre ainsi obtenu
US7566701B2 (en) *	2004-09-07	2009-07-28	Archemix Corp.	Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
AU2005282380A1 (en) *	2004-09-07	2006-03-16	Archemix Corp.	Aptamer medicinal chemistry
JP2008512098A (ja)	2004-09-07	2008-04-24	アーケミックスコーポレイション	フォン・ビルブラント因子に対するアプタマー、および血栓性疾患の処置剤としてのその使用
US7645860B2 (en)	2006-03-31	2010-01-12	Baxter Healthcare S.A.	Factor VIII polymer conjugates
WO2008150495A2 (fr) *	2007-06-01	2008-12-11	Archemix Corp.	Formulations d'aptamère vwf et procédés d'utilisation
FR2920429B1 (fr) *	2007-08-30	2012-10-05	Lfb Biotechnologies	Procede de purification du facteur viii et du facteur von willebrand
US11197916B2 (en) *	2007-12-28	2021-12-14	Takeda Pharmaceutical Company Limited	Lyophilized recombinant VWF formulations
ATE525062T1 (de) *	2007-12-28	2011-10-15	Baxter Int	Gegendruckfiltration von proteinen
IT1396528B1 (it)	2009-01-19	2012-12-14	Kedrion Spa	Nuovo processo di purificazione altamente selettivo di due proteine plasmatiche: von willebrand factor (vwf) e fibronectina (fn).
RU2579977C2 (ru)	2009-11-13	2016-04-10	Грифольс Терапьютикс Инк.	СОДЕРЖАЩИЕ ФАКТОР ФОН ВИЛЛЕБРАНДА (vWF) ПРЕПАРАТЫ И СПОСОБЫ, НАБОРЫ И ПРИМЕНЕНИЯ, СВЯЗАННЫЕ С НИМИ
EP2652491B1 (fr)	2010-12-15	2017-11-29	Baxalta GmbH	Collection d'eluat avec gradient de conductivite
JP6236948B2 (ja) *	2013-07-17	2017-11-29	東ソー株式会社	抗体精製用溶出液および当該溶出液を用いた抗体精製方法
EP3205665A1 (fr) *	2016-02-11	2017-08-16	Octapharma AG	Procédé de séparation de facteur viii à partir de produits sanguins
CA3094644A1 (fr)	2018-03-21	2019-09-26	Baxalta Incorporated	Separation de vwf et de propeptide de vwf par des procedes chromatographiques

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1982004395A1 (fr)	1981-06-18	1982-12-23	Erik Gustaf Birger Blombaeck	Procede de purification et de concentration du complexe de facteur viii
US4361509A (en) *	1981-12-14	1982-11-30	Scripps Clinic And Research Foundation	Ultrapurification of factor VIII using monoclonal antibodies
FR2570276B1 (fr)	1984-09-18	1987-09-04	Immunotech Sa	Procede d'obtention du complexe fviii/vwf a usage therapeutique et produits en resultant
US5200510A (en) *	1987-06-16	1993-04-06	Zymogenetics, Inc.	Method for purifying factor viii:c, von willebrand factor and complexes thereof
US5006642A (en) *	1987-06-29	1991-04-09	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Purification of von Willebrand Factor by affinity chromatography
US4774323A (en) *	1987-06-29	1988-09-27	Rorer Pharmaceutical Corporation	Purification of von Willebrand Factor solutions using gel permeation chromatography
DE3904354A1 (de)	1989-02-14	1990-08-16	Behringwerke Ag	Pasteurisiertes, gereinigtes von willebrand-faktor-konzentrat und verfahren zu seiner herstellung
FR2665449B1 (fr)	1990-08-02	1995-04-14	Aquitaine Developp Transf Sang	Procede de fabrication de facteur von willebrand ayant une tres haute purete, depourvu en majeure partie de facteur antihemophilique (fviiic), et facteur von willebrand ainsi obtenu, ainsi qu'une composition pharmaceutique le contenant.
FR2662166A1 (fr) *	1990-05-18	1991-11-22	Fondation Nale Transfusion San	Procede de preparation de facteur viii de tres haute purete comprenant une etape rapide d'immunoadsorption.
WO1993022336A1 (fr)	1992-04-30	1993-11-11	Alpha Therapeutic Corporation	Solubilisation et stabilisation ameliorees du complexe du facteur viii
IT1256622B (it)	1992-12-04	1995-12-12	Sclavo Spa	Processo per l'estrazione del complesso fattore viii-fattore von willebrand (fviii:c-fvw) da plasma umano totale.
DE4435485C1 (de)	1994-10-04	1996-03-21	Immuno Ag	Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
DE4435392B4 (de) *	1994-10-04	2008-02-07	Immuno Ag	Verfahren zur Trennung von vWF in hochmolekularen vWF und niedermolekularen vWF
AT403764B (de)	1996-03-15	1998-05-25	Immuno Ag	Stabiler faktor viii/vwf-komplex
CA2251558C (fr)	1996-04-12	2005-11-22	Immuno Aktiengesellschaft	Complexe du facteur viii hautement purifie
AT403765B (de) *	1996-04-12	1998-05-25	Immuno Ag	Verfahren zur herstellung einer präparation enthaltend einen hochgereinigten komplex

1997
- 1997-02-27 AT AT0033997A patent/AT406867B/de not_active IP Right Cessation
1998
- 1998-02-18 ES ES98903938T patent/ES2285758T3/es not_active Expired - Lifetime
- 1998-02-18 WO PCT/AT1998/000033 patent/WO1998038218A1/fr not_active Ceased
- 1998-02-18 CA CA002282842A patent/CA2282842C/fr not_active Expired - Lifetime
- 1998-02-18 JP JP53705598A patent/JP4250769B2/ja not_active Expired - Lifetime
- 1998-02-18 AT AT98903938T patent/ATE359302T1/de active
- 1998-02-18 DE DE59813968T patent/DE59813968D1/de not_active Expired - Lifetime
- 1998-02-18 EP EP98903938A patent/EP1012191B1/fr not_active Expired - Lifetime
- 1998-02-18 SI SI9830884T patent/SI1012191T1/sl unknown
- 1998-02-18 DK DK98903938T patent/DK1012191T3/da active
- 1998-02-18 AU AU61998/98A patent/AU734277B2/en not_active Expired
- 1998-02-18 US US09/367,362 patent/US6579723B1/en not_active Expired - Lifetime
- 1998-02-25 AR ARP980100834A patent/AR010120A1/es not_active Application Discontinuation
- 1998-02-25 AR ARP980100836A patent/AR010122A1/es active IP Right Grant
1999
- 1999-08-24 NO NO19994084A patent/NO323861B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
DK1012191T3 (da)	2007-08-06
EP1012191B1 (fr)	2007-04-11
CA2282842C (fr)	2010-02-02
CA2282842A1 (fr)	1998-09-03
WO1998038218A1 (fr)	1998-09-03
AU6199898A (en)	1998-09-18
ATA33997A (de)	2000-02-15
AR010122A1 (es)	2000-05-17
DE59813968D1 (de)	2007-05-24
AR010120A1 (es)	2000-05-17
JP4250769B2 (ja)	2009-04-08
AU734277B2 (en)	2001-06-07
ATE359302T1 (de)	2007-05-15
NO994084L (no)	1999-10-19
EP1012191A1 (fr)	2000-06-28
AT406867B (de)	2000-10-25
SI1012191T1 (sl)	2007-08-31
JP2001513762A (ja)	2001-09-04
NO994084D0 (no)	1999-08-24
ES2285758T3 (es)	2007-11-16
US6579723B1 (en)	2003-06-17

Legal Events

Date	Code	Title	Description
2015-10-26	CHAD	Change of the owner's name or address (par. 44 patent law, par. patentforskriften)	Owner name: BAXALTA INCORPORATED, CH
2018-03-12	MK1K	Patent expired

Publication	Publication Date	Title
AU645172B2 (en)	1994-01-06	Process for an industrial-scale preparation of a standardized human von Willebrand factor concentrate of very high purity and suitable for therapeutic use
US6924151B2 (en)	2005-08-02	Stable factor VIII/vWF-complex
US4495175A (en)	1985-01-22	Preparation of highly purified human antihemophilic factor
CA2282842C (fr)	2010-02-02	Procede permettant d'obtenir un facteur de von willebrand (vwf) ou un complexe facteur viii
AU737986B2 (en)	2001-09-06	Purification of von willebrand factor by cation exchange chromatography
NO180741B (no)	1997-03-03	Fremgangsmåte for isolering av Faktor VIII
NO964758L (no)	1997-05-12	Anvendelse av von Willebrand-faktor og farmasöytiske preparater
CN106414491A (zh)	2017-02-15	一种制备FVIII:C/FVIII:Ag比例提高的因子VIII的方法
JP4741178B2 (ja)	2011-08-03	Ｖｉｉｉ因子：ｃ含有フォンビルブラント因子の濃縮物およびそれに関連する方法
US6307032B1 (en)	2001-10-23	Highly purified factor VIII complex
US20020019036A1 (en)	2002-02-14	Von willebrand factor derivatives and methods of isolating proteins that bind to von willebrand factor
US10889630B2 (en)	2021-01-12	Method of separating Factor VIII from blood products
EP2155784A1 (fr)	2010-02-24	Procédé de chromatographie pour obtenir un complexe fviii/vwf avec différents rapports entre ces deux protéines, s'utilisant dans le traitement de l'hémophilie a et de la maladie de von willebrand
HUP9903789A2 (hu)	2000-03-28	von Willebrand-faktor származék, valamint eljárás proteinek izolálására
CA2251558C (fr)	2005-11-22	Complexe du facteur viii hautement purifie
Ruttyn et al.	1989	Chromatography of human plasma on aminohexyl sepharose: Separation of factor VIII/vWf and behaviour of factors II, VII, IX and X and antithrombin III
Aronson et al.	1981	Characterization Of The In Vitro “Factor VIII Bypassing Activity”
Brown et al.	1981	Interaction Of Factor VIII/Von Willebrand Factor With Phospholipid Vesicles
Vehar	1981	Cleavage Of Reduced Factor VIII/VON Willebrand Factor Subunits By Thrombin Or Factor Xa
Thomas et al.	1981	The Development Of Monoclonal Antibodies To Factor VIII Related Antigen (VIIIRAG)
de Lille	1982	Burnouf-Radosevich et a1.
Brind	1978	lins. 13, 14 Ultrafiltratio of concentrates 18